Cardiac Science and Cambridge Heart team up to develop MTWA module

Nov 13 2009

Cardiac Science Corporation [NASDAQ: CSCX], a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, and Cambridge Heart, Inc., [OTCBB-CAMH], a developer of noninvasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest, today announced a partnership pursuant to a Development, Supply and Distribution Agreement Cambridge Heart previously announced on June 23, 2009.

Under the Agreement, the Companies are collaborating to develop a Microvolt T-Wave Alternans (MTWA) module, which will be integrated with Cardiac Science’s cardiac stress test systems.

“We’re continually looking for ways to extend our leadership of the stress market. The development of MTWA as an add-on module for our stress systems allows us to bring new technology to our customers without asking them for a large capital outlay,” said Dave Marver, Cardiac Science president and chief executive officer. “This is consistent with our strategy to help our physician customers by offering simple, cost-effective, and efficient devices.”

“Our partnership with Cardiac Science allows us to have our MTWA technology distributed to cardiologists and primary care physicians through a large, world-class and well-established distribution organization,” said Ali Haghighi-Mood, president and chief executive officer of Cambridge Heart. “Our module strategy is intended to make our MTWA technology more accessible to the physicians who treat the 10- to 12-million higher-risk cardiac patients we believe can benefit from an annual MTWA test. Reaching even a modest percentage of those patients will create a great deal of value for Cambridge Heart, Cardiac Science and their physician customers and, ultimately, for their patients.”

Cambridge Heart has completed the prototype development of the module, which is now subject to industry standard validation and verification processes, and regulatory approval.

Source: Cardiac Science Corporation